

2023 U.K. Tumor Markers Diagnostic Testing Market Assessment of Business Opportunities-Oncogenes, Biomarkers, GFs, CSFs, Hormones, Stains, Lymphokines-2022 Competitive Shares and Strategies, 2022-2027 Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

<https://marketpublishers.com/r/2A8179DA6D7EEN.html>

Date: June 2023

Pages: 0

Price: US\$ 2,000.00 (Single User License)

ID: 2A8179DA6D7EEN

Abstracts

LeadingMarketResearch.com's new report is a study of the major business opportunities emerging in the UK cancer diagnostics market during the next five years. The report examines trends in the UK cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

The report is available by section, and can be customized to specific information needs and budget.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer

therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

UK Market Overview

Five-year test volume and sales projections.

Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

Estimated universe of laboratories performing cancer diagnostic testing.

Cancer statistics, etiology and recent developments.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

Biochemical Markers

Oncogenes

Growth Factors

Hormones

Colony Stimulating Factors

Lymphokines

Immunohistochemical Stains, and others.

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

Sales and market shares of major cancer diagnostic product suppliers by individual test.

Five-year test volume and sales forecasts for major tumor markers by market segment, including:

Hospitals

Commercial/Private Laboratories

Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays,

chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:

Abbott, Affymetrix, Beckman Coulter/Danaher/Cepheid, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujifilm Wako, Fujirebio, Grifols, Hologic, Leica Biosystems, PerkinElmer, Qiagen, QuidelOrtho, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher, and others.

Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology
 - 1. Breast Cancer
 - 2. Lung Cancer
 - 3. Colon and Rectum Cancer
 - 4. Prostate Cancer

5. Stomach Cancer

6. Leukemia

7. Lymphoma

8. Oral Cancer

9. Skin Cancer

10. Uterine Cancer

11. Ovarian Cancer

12. Bladder Cancer

B. Major Current and Emerging Cancer Diagnostic Tests

1. Introduction

2. Tumor Marker Classification

3. ACTH

4. Alpha-Fetoprotein (AFP)

5. Beta-2 Microglobulin

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. Calcitonin

10. Carcinoembryonic Antigen (CEA)

11. Estrogen and Progesterone Receptors

12. Ferritin

13. Gastrin

14. Human Chorionic Gonadotropin (HCG)

15. Insulin

16. NSE

17. Occult Blood

18. PAP Smear/HPV

19. Prostatic Acid Phosphatase (PAP)

20. Prostate-Specific Antigen (PSA)

21. Squamous Cell Carcinoma Antigen (SCC)

22. T and B Lymphocytes

23. TdT

24. Thyroglobulin

25. Tissue Polypeptide Antigen (TPA)

26. Biochemical Tumor Markers

27. Oncogenes

Abl/abl-bcr

AIB1

BCL-2

BRCA1

CD44

C-fos

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src and others

28. Polypeptide Growth Factors

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

ECFR

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

Alpha-Interferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

N-Acetylglucosamine

Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA

CA 72-4/TAG-72

CA

CA-242

CA-549

CAM

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

CU18

DR-70

DU-PAN-2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

FSH

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15

Glucagon

Glycoamines

H23

Her-2

Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor
Myosin
NEA-130
NMP22
OA-519
Opioid Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL

Selectin

Sialic Acid

Sialyl SSEA-1/SLX

SN10

Somatostatin

TA-90

TABA

Tachykinin

TAG

TPS

Troponin

Tubulin

VCAM

VEGF

Villen and others

C. Cancer Diagnostic Testing Instrumentation Review and Market Needs

D. Current and Emerging Cancer Diagnostic Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

3. Molecular Diagnostics

4. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. Artificial Intelligence

6. Flow Cytometry

7. Two Dimensional Gel Electrophoresis (2-DGE)

8. Biosensors

9. Competing/Complementing Technologies

E. Personal Testing

VIII. COUNTRY ANALYSIS

A. Executive Summary

B. Business Environment

C. Market Structure

D. Market Dynamics, Trends, Size and Growth

Volume Forecasts by Test and Market Segment

Sales Forecasts by Test and Market Segment

Major Supplier Sales and Market Shares

IX. COMPETITIVE PROFILES

The report provides strategic assessments of over 30 leading cancer diagnostics market players

and start-up companies with innovative technologies and products, including:

Abbott

Affymetrix

Beckman Coulter/Danaher/Cepheid

Becton Dickinson

bioMerieux

Bio-Rad

DiaSorin

Eiken Chemical

Elitech Group

Enzo Biochem

Fujifilm Wako

Fujirebio

Grifols

Hologic

Leica Biosystems

PerkinElmer

Qiagen

QuidelOrtho

Roche

Siemens Healthineers

Takara Bio

Thermo Fisher and others.

I would like to order

Product name: 2023 U.K. Tumor Markers Diagnostic Testing Market Assessment of Business Opportunities-Oncogenes, Biomarkers, GFs, CSFs, Hormones, Stains, Lymphokines-2022 Competitive Shares and Strategies, 2022-2027 Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

Product link: <https://marketpublishers.com/r/2A8179DA6D7EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2A8179DA6D7EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970